Clinical Trial Update: Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ustekinumab to treat immune checkpoint inhibitor-related diarrhea and colitis in cancer patients is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Stelara (ustekinumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Cancer | Phase 2 | Status: RECRUITING